Vet World Vol.18 June-2025 Article - 25
Research Article
Veterinary World, 18(6): 1675-1684
https://doi.org/10.14202/vetworld.2025.1675-1684
Immunoinformatic development of a multiepitope messenger RNA vaccine targeting lipoate protein ligase and dihydrolipoamide dehydrogenase proteins of Mycoplasma bovis in cattle
1. Department of Internal and Preventive Medicine, College of Veterinary Medicine, University of Al-Qadisiyah, Al-Diwaniyah, Iraq.
2. Department of Physiology, Pharmacology and Biochemistry, College of Veterinary Medicine, University of Al-Qadisiyah, Al-Diwaniyah, Iraq.
Background and Aim: Mycoplasma bovis is a significant pathogen in cattle, causing respiratory, reproductive, and mammary diseases, leading to substantial economic losses. Conventional control measures remain ineffective due to antimicrobial resistance and the absence of an approved vaccine. This study aimed to develop a multiepitope messenger RNA (mRNA)-based vaccine against M. bovis using immunoinformatic and molecular modeling approaches.
Materials and Methods: Two conserved surface-exposed proteins – lipoate protein ligase (LplA) and dihydrolipoamide dehydrogenase (PdhD) – were selected as vaccine targets. T- and B-cell epitopes were predicted using Immune Epitope Database and evaluated for antigenicity, allergenicity, toxicity, and conservancy. Selected epitopes were linked using specific amino acid linkers and combined with a resuscitation-promoting factor E (RpfE) adjuvant and untranslated regions (hemoglobin subunit beta and rabbit beta-globin) to improve translation and stability. The vaccine construct was modeled and validated through physicochemical profiling, secondary and tertiary structure prediction, molecular-docking with bovine toll-like receptors 4 (TLR4), and codon optimization. Molecular dynamics simulations were conducted to assess the stability of the vaccine-receptor complex.
Results: The modeled vaccine construct contained five cytotoxic T lymphocyte, six helper T lymphocyte, and five B-cell epitopes. The construct was predicted to be highly antigenic (score: 0.835), non-allergenic, and non-toxic. Structural validation showed 93.5% of residues in favored regions of the Ramachandran plot and a Z-score of −10.6. Docking simulations revealed strong binding affinity to bovine TLR4, supported by robust molecular dynamics simulation outcomes, including high stability, low eigenvalues, and favorable covariance patterns. Codon optimization yielded a guanine-cytosine content of 59.8% and a codon adaptation index of 0.87, indicating efficient expression in cattle. The predicted mRNA structure exhibited good thermodynamic stability (minimum free energy: −321.42 kcal/mol).
Conclusion: This study presents a computationally designed mRNA vaccine candidate against M. bovis based on LplA and PdhD epitopes. The construct demonstrated promising immunogenicity, structural integrity, and receptor-binding properties, representing a viable vaccine strategy. Nonetheless, in vitro and in vivo validation is essential to confirm the construct’s efficacy and safety in cattle.
Keywords: cattle, epitope prediction, immunoinformatic, messenger RNA vaccine, multiepitope vaccine, Mycoplasma bovis.
How to cite this article: Al-Fetly DR, Alsallami D, and Alsultan A (2025) Immunoinformatic development of a multiepitope messenger RNA vaccine targeting lipoate protein ligase and dihydrolipoamide dehydrogenase proteins of Mycoplasma bovis in cattle, Veterinary World, 18(6): 1675-1684.
Received: 28-02-2025 Accepted: 27-05-2025 Published online: 19-06-2025
Corresponding author: E-mail:
DOI: 10.14202/vetworld.2025.1675-1684
Copyright: Al-Fetly, et al. This article is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.